The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Pathophysiologic Mechanisms and Potential Biomarkers in Diabetic Kidney Disease
Open accessAbstract
Although diabetic kidney disease (DKD) remains the leading cause of end-stage kidney disease eventually requiring chronic kidney replacement therapy, the prevalence of DKD has failed to decline over the past 30 years. In order to reduce disease prevalence, extensive research has been ongoing to improve prediction of DKD onset and progression. Although the most commonly used markers of DKD are albuminuria and estimated glomerular filtration rate, their limitations have encouraged researchers to search for novel biomarkers that could improve risk stratification. Considering that DKD is a complex disease process that involves several pathophysiologic mechanisms such as hyperglycemia induced inflammation, oxidative stress, tubular damage, eventually leading to kidney damage and fibrosis, many novel biomarkers that capture one specific mechanism of the disease have been developed. Moreover, the increasing use of high-throughput omic approaches to analyze biological samples that include proteomics, metabolomics, and transcriptomics has emerged as a strong tool in biomarker discovery. This review will first describe recent advances in the understanding of the pathophysiology of DKD, and second, describe the current clinical biomarkers for DKD, as well as the current status of multiple potential novel biomarkers with respect to protein biomarkers, proteomics, metabolomics, and transcriptomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397 · cited 17×
“After a median follow-up of 2.5 years, high-risk patients defined by CKD-273 were more likely to develop microalbuminuria, even after adjustments for baseline risk factors such as HbA1c, systolic blood pressure, baseline albuminuria and eGFR [102].”
BackgroundInfluentialWhelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000065 · Cited by 7,391
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000066 · Cited by 4,347
Stevens, P. E., Levin, A., & for the Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members* (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-11-201306040-00007 · Cited by 3,607
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Diabetic Kidney Disease: Challenges, Progress, and Possibilities
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11491116 · Cited by 2,898
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845 · cited 1×
“ny) failed to improve endothelial function [60], suggesting that CVD benefits associated with the use of SGLT2 inhibitors may have been attributable to mechanisms other than reduced inflammation and endothelial dysfunction [61].”
BackgroundAndrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Kidney Injury Molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury
Han, W. K., Bailly, V., Abichandani, R., Thadhani, R., & Bonventre, J. V. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00433.x · Cited by 1,929
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Changes in diabetes-related complications in the United States, 1990-2010
Gregg, E. W., Li, Y., Wang, J., Rios Burrows, N., Ali, M. K., Rolka, D., Williams, D. E., & Geiss, L. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1310799 · Cited by 1,749
The J-Curve Phenomenon in Hypertension
Kang, Y.-Y., & Wang, J.-G. (2016) · Pulse · doi:10.1159/000446922 · Cited by 1,530
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306033 · Cited by 1,030
Nonenzymatic Glycosylation and the Pathogenesis of Diabetic Complications
BROWNLEE, M., VLASSARA, H., & CERAMI, A. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-4-527 · Cited by 1,007
Wu, L. L., Chiou, C.-C., Chang, P.-Y., & Wu, J. T. (2004) · Clinica Chimica Acta · doi:10.1016/j.cccn.2003.09.010 · Cited by 990
Xie, X., Atkins, E., Lv, J., Bennett, A., Neal, B., Ninomiya, T., Woodward, M., MacMahon, S., Turnbull, F., Hillis, G. S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00805-3 · Cited by 980
Ziyadeh, F. N., Hoffman, B. B., Han, D. C., Iglesias-de la Cruz, M. C., Hong, S. W., Isono, M., Chen, S., McGowan, T. A., & Sharma, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120055097 · Cited by 907
Parving, H.-H., Smidt, U., Andersen, A., & Svendsen, P. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92462-5 · Cited by 867
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
Anders, H.-J., Huber, T. B., Isermann, B., & Schiffer, M. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0001-y · Cited by 796
Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001293 · Cited by 777
6. Glycemic Targets: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s006 · Cited by 762
Xia, Y., Dawson, V. L., Dawson, T. M., Snyder, S. H., & Zweier, J. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.13.6770 · Cited by 718
Sharma, K., Jin, Y., Guo, J., & Ziyadeh, F. N. (1996) · Diabetes · doi:10.2337/diab.45.4.522 · Cited by 662
Cooper-DeHoff, R. M., Gong, Y., Handberg, E. M., Bavry, A. A., Denardo, S. J., Bakris, G. L., & Pepine, C. J. (2010) · JAMA · doi:10.1001/jama.2010.884 · Cited by 651
Relationship between Oxidative Stress and Inflammatory Cytokines in Diabetic Nephropathy
Elmarakby, A. A., & Sullivan, J. C. (2012) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00218.x · Cited by 641
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Pathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Tomino, Y. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368458 · Cited by 566
Update of pathophysiology and management of diabetic kidney disease
Lin, Y.-C., Chang, Y.-H., Yang, S.-Y., Wu, K.-D., & Chu, T.-S. (2018) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2018.02.007 · Cited by 562
Metabolic Syndrome and Kidney Disease: A Systematic Review and Meta-analysis
Thomas, G., Sehgal, A. R., Kashyap, S. R., Srinivas, T. R., Kirwan, J. P., & Navaneethan, S. D. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02180311 · Cited by 553 · cited 1×
“Although the metabolic syndrome, which is associated with insulin resistance, obesity, and hypertension, is strongly associated with the development of CKD and albuminuria [69], not all patients with the metabolic syndrome and T2DM develop albuminuria [70].”
BackgroundChow, F., Ozols, E., Nikolic-Paterson, D. J., Atkins, R. C., & Tesch, G. H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00367.x · Cited by 551
Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease
Good, D. M., Zürbig, P., Argilés, À., Bauer, H. W., Behrens, G., Coon, J. J., Dakna, M., Decramer, S., Delles, C., Dominiczak, A. F., et al. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.001917 · Cited by 524
Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes
Niewczas, M. A., Gohda, T., Skupien, J., Smiles, A. M., Walker, W. H., Rosetti, F., Cullere, X., Eckfeldt, J. H., Doria, A., Mayadas, T. N., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011060627 · Cited by 485
Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy
Shahzad, K., Bock, F., Dong, W., Wang, H., Kopf, S., Kohli, S., Al-Dabet, M. M., Ranjan, S., Wolter, J., Wacker, C., et al. (2015) · Kidney International · doi:10.1038/ki.2014.271 · Cited by 411
Jha, J. C., Gray, S. P., Barit, D., Okabe, J., El-Osta, A., Namikoshi, T., Thallas-Bonke, V., Wingler, K., Szyndralewiez, C., Heitz, F., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013070810 · Cited by 352
Metabolomics for clinical use and research in chronic kidney disease
Hocher, B., & Adamski, J. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.30 · Cited by 339
Pirfenidone for Diabetic Nephropathy
Sharma, K., Ix, J. H., Mathew, A. V., Cho, M., Pflueger, A., Dunn, S. R., Francos, B., Sharma, S., Falkner, B., McGowan, T. A., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010101049 · Cited by 319
Urinary Exosomal MicroRNAs in Incipient Diabetic Nephropathy
Barutta, F., Tricarico, M., Corbelli, A., Annaratone, L., Pinach, S., Grimaldi, S., Bruno, G., Cimino, D., Taverna, D., Deregibus, M. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073798 · Cited by 317
Low Glomerular Filtration Rate in Normoalbuminuric Type 1 Diabetic Patients
Caramori, M. L., Fioretto, P., & Mauer, M. (2003) · Diabetes · doi:10.2337/diabetes.52.4.1036 · Cited by 301
Okada, S., Shikata, K., Matsuda, M., Ogawa, D., Usui, H., Kido, Y., Nagase, R., Wada, J., Shikata, Y., & Makino, H. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2586 · Cited by 298
Kolch, W., Neusüß, C., Pelzing, M., & Mischak, H. (2005) · Mass Spectrometry Reviews · doi:10.1002/mas.20051 · Cited by 290
Moriwaki, Y., Yamamoto, T., Shibutani, Y., Aoki, E., Tsutsumi, Z., Takahashi, S., Okamura, H., Koga, M., Fukuchi, M., & Hada, T. (2003) · Metabolism · doi:10.1053/meta.2003.50096 · Cited by 270
Biomarkers of diabetic kidney disease
Colhoun, H. M., & Marcovecchio, M. L. (2018) · Diabetologia · doi:10.1007/s00125-018-4567-5 · Cited by 270
Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy
Hasegawa, G., Nakano, K., Sawada, M., Uno, K., Shibayama, Y., Ienaga, K., & Kondo, M. (1991) · Kidney International · doi:10.1038/ki.1991.308 · Cited by 268
Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy
Zürbig, P., Jerums, G., Hovind, P., MacIsaac, R. J., Mischak, H., Nielsen, S. E., Panagiotopoulos, S., Persson, F., & Rossing, P. (2012) · Diabetes · doi:10.2337/db12-0348 · Cited by 266
Tofte, N., Lindhardt, M., Adamova, K., Bakker, S. J. L., Beige, J., Beulens, J. W. J., Birkenfeld, A. L., Currie, G., Delles, C., Dimos, I., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30026-7 · Cited by 262
Shigiyama, F., Kumashiro, N., Miyagi, M., Ikehara, K., Kanda, E., Uchino, H., & Hirose, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0564-0 · Cited by 249
Tumor necrosis factor induces glomerular damage in the rabbit.
Bertani, T., Abbate, M., Zoja, C., Corna, D., Perico, N., Ghezzi, P., & Remuzzi, G. (1989) · Europe PMC (PubMed Central) · Cited by 246
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
Warren, A. M., Knudsen, S. T., & Cooper, M. E. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1624721 · Cited by 245
Plasma Biomarkers and Kidney Function Decline in Early and Established Diabetic Kidney Disease
Coca, S. G., Nadkarni, G. N., Huang, Y., Moledina, D. G., Rao, V., Zhang, J., Ferket, B., Crowley, S. T., Fried, L. F., & Parikh, C. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016101101 · Cited by 239
(2014) · PubMed · Cited by 237
Treatment of Diabetic Kidney Disease: Current and Future
Yamazaki, T., Mimura, I., Tanaka, T., & Nangaku, M. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0217 · Cited by 237
Dubin, R. F., & Rhee, E. P. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07420619 · Cited by 204
Menne, J., Eulberg, D., Beyer, D., Baumann, M., Saudek, F., Valkusz, Z., Więcek, A., Haller, H., & for the Emapticap Study Group (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv459 · Cited by 201
Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy
Hirayama, A., Nakashima, E., Sugimoto, M., Akiyama, S.-I., Sato, W., Maruyama, S., Matsuo, S., Tomita, M., Yuzawa, Y., & Soga, T. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6412-x · Cited by 191
Gorin, Y., Cavaglieri, R. C., Khazim, K., Lee, D.-Y., Bruno, F., Thakur, S., Fanti, P., Szyndralewiez, C., Barnes, J. L., Block, K., et al. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00396.2014 · Cited by 183
Barrera‐Chimal, J., & Jaisser, F. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13969 · Cited by 174
Vistisen, D., Andersen, G. S., Hulman, A., Persson, F., Rossing, P., & Jørgensen, M. E. (2019) · Diabetes Care · doi:10.2337/dc19-0349 · Cited by 167
Kamijo-Ikemori, A., Sugaya, T., Yasuda, T., Kawata, T., Ota, A., Tatsunami, S., Kaise, R., Ishimitsu, T., Tanaka, Y., & Kimura, K. (2011) · Diabetes Care · doi:10.2337/dc10-1392 · Cited by 167
Pena, M. J., Heerspink, H. J. L., Hellemons, M. E., Friedrich, T., Dallmann, G., Lajer, M., Bakker, S. J. L., Gansevoort, R. T., Rossing, P. R., de Zeeuw, D., et al. (2014) · Diabetic Medicine · doi:10.1111/dme.12447 · Cited by 162
Verma, S., Singh, P., Khurana, S., Ganguly, N. K., Kukreti, R., Saso, L., Rana, D. S., Taneja, V., & Bhargava, V. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.20.163 · Cited by 161
The role of oxidative stress and hypoxia in renal disease
Honda, T., Hirakawa, Y., & Nangaku, M. (2019) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.19.063 · Cited by 158
Kalantarinia, K., Awad, A. S., & Siragy, H. M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00237.x · Cited by 156
Schrauben, S. J., Shou, H., Zhang, X., Anderson, A. H., Bonventre, J. V., Chen, J., Coca, S. G., Furth, S. L., Greenberg, J. H., Gutiérrez, O. M., et al. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020040487 · Cited by 154
Biomarkers of rapid chronic kidney disease progression in type 2 diabetes
Looker, H. C., Colombo, M., Hess, S., Brosnan, M. J., Farran, B., Dalton, R. N., Wong, M. C., Turner, C., Palmer, C. N. A., Nogoceke, E., et al. (2015) · Kidney International · doi:10.1038/ki.2015.199 · Cited by 152
Han, L., Xia, J., Liang, Q.-L., Wang, Y., Wang, Y.-M., Hu, P., Li, P., & Luo, G. (2011) · Analytica Chimica Acta · doi:10.1016/j.aca.2011.01.034 · Cited by 144
A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus
Roscioni, S. S., de Zeeuw, D., Hellemons, M. E., Mischak, H., Zürbig, P., Bakker, S. J. L., Gansevoort, R. T., Reinhard, H., Persson, F., Lajer, M., et al. (2012) · Diabetologia · doi:10.1007/s00125-012-2755-2 · Cited by 143
Workshop: Endothelial Cell Dysfunction Leading to Diabetic Nephropathy
Goligorsky, M. S., Chen, J., & Brodsky, S. V. (2001) · Hypertension · doi:10.1161/01.hyp.37.2.744 · Cited by 141
Urinary Cystatin C and Tubular Proteinuria Predict Progression of Diabetic Nephropathy
Kim, S. S., Song, S. H., Kim, I. J., Jeon, Y. K., Kim, B. H., Kwak, I. S., Lee, E. K., & Kim, Y. K. (2012) · Diabetes Care · doi:10.2337/dc12-0849 · Cited by 139
Sharma, D., Bhattacharya, P., Kalia, K., & Tiwari, V. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.04.010 · Cited by 135
Nangaku, M., Kanda, H., Takama, H., Ichikawa, T., Hase, H., & Akizawa, T. (2020) · Kidney International Reports · doi:10.1016/j.ekir.2020.03.030 · Cited by 133
Xu, G., Yao, Q., Weng, Q., Su, B. L., Zhang, X., & Xiong, J. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2004.04.016 · Cited by 127
de Carvalho, J. A. M., Tatsch, E., Hausen, B. S., Bollick, Y. S., Moretto, M. B., Duarte, T., Duarte, M. M. M. F., Londero, S. W. K., Premaor, M. O., Comim, F. V., et al. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.10.016 · Cited by 126
Nielsen, S. E., Sugaya, T., Hovind, P. H., Baba, T., Parving, H., & Rossing, P. R. (2010) · Diabetes Care · doi:10.2337/dc09-2242 · Cited by 124
Salim, H. M., Fukuda, D., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00043 · Cited by 123
Zhang, J., Yan, L., Chen, W., Lin, L., Song, X., Yan, X., Hang, W., & Huang, B. (2009) · Analytica Chimica Acta · doi:10.1016/j.aca.2009.02.027 · Cited by 122
Navarro‐González, J. F., Mora, C., Muros, M., & Garcı́a, J. G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010001 · Cited by 121
Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP
Buckley, L. F., Dixon, D. L., Wohlford, G. F., Wijesinghe, D. S., Baker, W. L., & Tassell, B. W. V. (2017) · Diabetes Care · doi:10.2337/dc17-1366 · Cited by 120
Diabetes Induces Aberrant DNA Methylation in the Proximal Tubules of the Kidney
Marumo, T., Yagi, S., Kawarazaki, W., Nishimoto, M., Ayuzawa, N., Watanabe, A., Ueda, K., Hirahashi, J., Hishikawa, K., Sakurai, H., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070665 · Cited by 118
‘Progressive diabetic nephropathy. How useful is microalbuminuria?: contra’
MacIsaac, R. J., Ekinci, E. I., & Jerums, G. (2014) · Kidney International · doi:10.1038/ki.2014.98 · Cited by 111
Comprehensive approach to diabetic nephropathy
Satirapoj, B., & Adler, S. G. (2014) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.08.001 · Cited by 109
Lindhardt, M. K., Persson, F., Zürbig, P., Stalmach, A., Mischak, H., de Zeeuw, D., Heerspink, H. J. L., Klein, R., Orchard, T. J., Porta, M., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw292 · Cited by 108
Hypertension Management in Diabetes: 2018 Update
Passarella, P., Киселева, Т. А., Valeeva, F. V., & Gosmanov, A. R. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0085 · Cited by 107
Panduru, N. M., Forsblom, C. M., Saraheimo, M., Thorn, L. M., Bierhaus, A., Humpert, P. M., Groop, P., & on behalf of the FinnDiane Study Group (2013) · Diabetes Care · doi:10.2337/dc12-1868 · Cited by 106
Hyperglycemic switch from mitochondrial nitric oxide to superoxide production in endothelial cells
Brodsky, S. V., Gao, S., Li, H., & Goligorsky, M. S. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00196.2002 · Cited by 101
Tamborlane, W. V., Puklin, J. E., Bergman, M., Verdonk, C. A., Mc, R., Felig, P., Genel, M., & Sherwin, R. (1982) · PubMed · Cited by 99
Boels, M. G. S., Koudijs, A., Avramut, M. C., Sol, W. M. P. J., Wang, G., van Oeveren‐Rietdijk, A. M., van Zonneveld, A. J., de Boer, H. C., van der Vlag, J., van Kooten, C., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.07.020 · Cited by 97
Argyropoulos, C., Wang, K., Bernardo, J., Ellis, D., Orchard, T. J., Galas, D. J., & Johnson, J. P. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4071498 · Cited by 95
“Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL
Lacquaniti, A., Donato, V., Pintaudi, B., Vieste, G. D., Chirico, V., Buemi, A., Benedetto, A. D., Arena, A., & Buemi, M. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0485-7 · Cited by 95
The Role of Oxidative Stress in the Pathogenesis of Diabetic Vascular Complications
Sasaki, S., & Inoguchi, T. (2012) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2012.36.4.255 · Cited by 92
Kwan, B., Fuhrer, T., Zhang, J., Darshi, M., Espen, B. V., Montemayor, D., de Boer, I. H., Dobre, M. A., Hsu, C., Kelly, T. N., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.01.019 · Cited by 91
Lopes-Virella, M. F., Baker, N. L., Hunt, K. J., Cleary, P. A., Klein, R. L., & Virella, G. (2013) · Diabetes Care · doi:10.2337/dc12-2521 · Cited by 82
Navarro‐González, J. F., Sánchez-Niño, M. D., Donate‐Correa, J., Martín‐Núñez, E., Ferri, C. M., Pérez‐Delgado, N., Górriz, J. L., Martínez‐Castelao, A., Ortíz, A., & Fernández, C. M. (2018) · Diabetes Care · doi:10.2337/dc18-0078 · Cited by 79
Metabolic Changes and Oxidative Stress in Diabetic Kidney Disease
Sakashita, M., Tanaka, T., & Inagi, R. (2021) · Antioxidants · doi:10.3390/antiox10071143 · Cited by 78
Urine haptoglobin levels predict early renal functional decline in patients with type 2 diabetes
Bhensdadia, N. M., Hunt, K. J., Lopes-Virella, M. F., Tucker, J. M., Mataria, M. R., Alge, J. L., Neely, B. A., Janech, M. G., & Arthur, J. M. (2013) · Kidney International · doi:10.1038/ki.2013.57 · Cited by 77
Mutter, S., Valo, E., Aittomäki, V., Nybo, K., Raivonen, L., Thorn, L. M., Forsblom, C. M., Sandholm, N., Würtz, P., & Groop, P. (2021) · Diabetologia · doi:10.1007/s00125-021-05584-3 · Cited by 75
Targeting the MCP-1/CCR2 System in Diabetic Kidney Disease
Giunti, S., Barutta, F., Perin, P. C., & Gruden, G. (2010) · Current Vascular Pharmacology · doi:10.2174/157016110793563816 · Cited by 73
An, J. H., Cho, Y. M., Yu, H. G., Jang, H. C., Park, K. S., Kim, S. Y., & Lee, H. K. (2009) · Journal of Korean Medical Science · doi:10.3346/jkms.2009.24.s1.s75 · Cited by 66
Donate‐Correa, J., Tagua, V. G., Ferri, C. M., Martín‐Núñez, E., Hernández-Carballo, C., Ureña, P., Ruiz‐Ortega, M., Ortíz, A., Fernández, C. M., & Navarro‐González, J. F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030287 · Cited by 66
Pentoxifylline for diabetic kidney disease
Shan, D., Wu, H. M., Yuan, Q. Y., Li, J., Zhou, R. L., & Liu, G. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006800.pub2 · Cited by 64
Sanchez, M., Roussel, R., Hadjadj, S., Moutairou, A., Marre, M., Velho, G., & Mohammedi, K. (2017) · Diabetologia · doi:10.1007/s00125-017-4510-1 · Cited by 63
Serdar, M. A., Sertoğlu, E., Uyanık, M., Tapan, S., Akın, K. O., Bilgi, C., & Kurt, İ. (2012) · Free Radical Research · doi:10.3109/10715762.2012.710902 · Cited by 61
Tanaka, A., Shimabukuro, M., Machii, N., Teragawa, H., Okada, Y., Shima, K. R., Takamura, T., Taguchi, I., Hisauchi, I., Toyoda, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-1177 · Cited by 60
SKUPIEN, J. K., Warram, J. H., Niewczas, M. A., Gohda, T., Malecki, M. T., Mychaleckyj, J. C., Gałecki, A. T., & Królewski, A. S. (2014) · Diabetes Care · doi:10.2337/dc13-1983 · Cited by 59
Noncoding RNAs as therapeutic targets in early stage diabetic kidney disease
Kato, M. V. (2018) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.2018.37.3.197 · Cited by 58
Kwon, G., Uddin, M. J., Lee, G.-Y., Jiang, S., Cho, A., Lee, J. H., Lee, S. R., Bae, Y. S., Moon, S. H., Lee, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18540 · Cited by 50
CKD273 Enables Efficient Prediction of Diabetic Nephropathy in Nonalbuminuric Patients
Zürbig, P., Mischak, H., Menne, J., & Haller, H. (2019) · Diabetes Care · doi:10.2337/dc18-1322 · Cited by 41
Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes
Pena, M. J., de Zeeuw, D., Mischak, H., Jankowski, J., Oberbauer, R. W., Woloszczuk, W., Benner, J., Dallmann, G., Mayer, B., Mayer, G. J., et al. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv252 · Cited by 39
Obesity-Induced Increase in Cystatin C Alleviates Tissue Inflammation
Dedual, M. A., Wueest, S., Challa, T. D., Lucchini, F. C., Aeppli, T. R. J., Borsigova, M., Mauracher, A. A., Vavassori, S., Schmid, J. P., Blüher, M., et al. (2020) · Diabetes · doi:10.2337/db19-1206 · Cited by 34
Moazzeni, S. S., Arani, R. H., Hasheminia, M., Tohidi, M., Azizi, F., & Hadaegh, F. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0109 · Cited by 33
Neutrophil Gelatinase-Associated Lipocalin as an Early Sign of Diabetic Kidney Injury in Children
Yıldırım, Z. N. Y., Nayır, A., Yılmaz, A., et al. (2015) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.2002 · Cited by 29
Hypertension Management in Diabetic Kidney Disease
Patney, V., Whaley‐Connell, A. T., & Bakris, G. L. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.175 · Cited by 25
(1985) · PubMed · Cited by 23
Oh, T. J., Moon, J.-Y., Hur, K. Y., Ko, S., Kim, H. J., Kim, T. H., Lee, D. W., & Moon, M. K. (2020) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.20.132 · Cited by 10
Cited by
Diabetic vascular diseases: molecular mechanisms and therapeutic strategies
Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01400-z · Cited by 704
Role of MCP-1 as an inflammatory biomarker in nephropathy
Liu, Y., Xu, K., Xiang, Y., Ma, B., Li, H., Li, Y., Shi, Y., Li, S., & Bai, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303076 · Cited by 93
Zhu, H.-M., Liu, N., Sun, D.-X., & Luo, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202298 · Cited by 12
“In addition, bioinformatic study of OS genes may assist in the identification of new diagnostic or prognostic indicators for DN, which may then be used to search for novel therapy targets (28, 29).”
Background
Metadata
- Authors
- Jung, C.-Y., & Yoo, T.-H.
- Venue
- Diabetes & Metabolism Journal
- Publisher
- Korean Diabetes Association
- Published
- 2022-03-31
- Volume
- 46
- Issue
- 2
- Pages
- 181-197
- ISSN
- 2233-6079 (ISSN-L)
- 2233-6087
- OpenAlex
- W4220922585
- Cited by
- 262
- References
- 119
- FWCI
- 23.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.